P/E ratio for Editas Medicine (EDIT)
P/E ratio as of April 2024 (TTM): -1.84
According to Editas Medicine 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.84459. At the end of 2022 the company had a P/E ratio of -2.76.
P/E ratio history for Editas Medicine from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.76 | -70.34% |
| 2021 | -9.32 | -73.56% |
| 2020 | -35.2 | 220.07% |
| 2019 | -11.0 | 12.74% |
| 2018 | -9.76 | -5.32% |
| 2017 | -10.3 | 92.52% |
| 2016 | -5.36 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | -0.4854 | -73.68% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | -2.69 | 46.02% | 🇬🇧 UK |
 Novavax NVAX | -0.5828 | -68.41% | 🇺🇸 USA |
 Novocure
NVCR | -6.48 | 251.36% | Jersey |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.